ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Clinical Validation of Automated Urinary Chemokine Assays for Non-Invasive Detection of Kidney Transplant Rejection: A Large Prospective Cohort Study

E. Van Loon1, C. Tinel1, J. Callemeyn1, M. Coemans1, A. Van Craenenbroeck1, T. Vaulet2, D. Anglicheau3, M. Naesens1

1Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, 2ESAT STADIUS Center for Dynamical Systems, KU Leuven, Leuven, Belgium, 3Department of Nephrology and Kidney Transplantation, Necker Hospital, Paris, France

Meeting: 2022 American Transplant Congress

Abstract number: 466

Keywords: Kidney transplantation, Monitoring, Non-invasive diagnosis, Rejection

Topic: Basic Science » Basic Clinical Science » 17 - Biomarkers: Clinical Outcomes

Session Information

Session Name: Biomarkers: Clinical Outcomes I

Session Type: Rapid Fire Oral Abstract

Date: Tuesday, June 7, 2022

Session Time: 3:30pm-5:00pm

 Presentation Time: 4:00pm-4:10pm

Location: Hynes Veterans Auditorium

*Purpose: Non-invasive diagnostic markers for kidney transplant rejection can provide useful information but often do not reach the clinical implementation stage. The chemokines CXCL9 and CXCL10 have been extensively studied as biomarkers for rejection. However, final validation in a sufficiently large, real-world prospective cohort is needed to determine the relation to rejection subtypes and clinical confounders, the context of use, and the added benefit for clinical practice.

*Methods: In this single-center prospective cohort study, we analyzed 1559 biopsy-paired urinary samples at both indication and protocol time points from 622 kidney transplants performed between April 2013 and July 2019. We quantified urinary CXCL9 and CXCL10 using automated immuno-assays and normalized the values to urinary creatinine. Next to evaluating the diagnostic performance for Banff-grade rejection, we also considered rejection as assessed by the molecular microscope.

*Results: The urinary chemokines strongly associated with the biopsy’s inflammation severity, when considering classical semi-quantitative histological scoring, but also when considering molecular rejection scores. The diagnostic performance of urinary chemokines alone was moderate for Banff acute rejection, and increased when considering treated rejections or molecular rejection instead (Figure 1). Taking into account confounding factors rather than excluding them, an integrated model of urinary chemokines with eGFR, donor-specific antibodies, time after transplantation and polyoma viremia had high diagnostic value for acute rejection (N=150) (ROCAUC 82.6%, 95% CI 78.9-86.2) and added value on top of clinical standard-of-care. The integrated score would help to safely avoid 59 protocol biopsies per 100 patients when the predicted rejection risk is below 10%.

*Conclusions: Integrating urinary chemokines and clinical markers allows for personalized non-invasive monitoring of rejection probability and enables to importantly and safely reduce the number of unnecessary biopsies. We anticipate this study paves the way to final implementation of urinary chemokine measurements as non-invasive markers for rejection in routine clinical follow-up after kidney transplantation.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Loon EVan, Tinel C, Callemeyn J, Coemans M, Craenenbroeck AVan, Vaulet T, Anglicheau D, Naesens M. Clinical Validation of Automated Urinary Chemokine Assays for Non-Invasive Detection of Kidney Transplant Rejection: A Large Prospective Cohort Study [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-validation-of-automated-urinary-chemokine-assays-for-non-invasive-detection-of-kidney-transplant-rejection-a-large-prospective-cohort-study/. Accessed June 7, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences